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Background: The HIV-1 pandemic is not the result of a static pathogen but a large genetically diverse and dynamic
viral population. The virus is characterized by a highly mutable genome rendering efforts to design a universal vaccine
a significant challenge and drives the emergence of drug resistant variants upon antiviral pressure. Gaining a
comprehensive understanding of the mutational tolerance of each HIV-1 genomic position is therefore of critical
importance.
Results: Here we combine high-density mutagenesis with the power of next-generation sequencing to gauge
the replication capacity and therefore mutational tolerability of single point mutations across the entire HIV-1
genome. We were able to achieve the evaluation of point mutational effects on viral replicative capacity for 5,553
individual HIV-1 nucleotide positions – representing 57% of the viral genome. Replicative capacity was assessed
at 3,943 nucleotide positions for a single alternate base change, 1,459 nucleotide positions for two alternate base
changes, and 151 nucleotide positions for all three possible alternate base changes. This resulted in the study of
how a total of 7,314 individual point mutations impact HIV-1 replication on a single experimental platform. We
further utilize the dataset for a focused structural analysis on a capsid inhibitor binding pocket.
Conclusion: The approach presented here can be applied to any pathogen that can be genetically manipulated
in a laboratory setting. Furthermore, the methodology can be utilized under externally applied selection conditions,
such as drug or immune pressure, to identify genetic elements that contribute to drug or host interactions, and
therefore mutational routes of pathogen resistance and escape.
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Currently ~35 million people are living with human im-
munodeficiency virus-1 (HIV-1) infection, the pathogen
responsible for acquired immunodeficiency syndrome
(AIDS), with tens of millions having died of AIDS-
related causes worldwide since the pandemic began
(UNAIDS. GAP Report; 2013). The virus rapidly evolves
due to the high error rate of the viral reverse transcript-
ase (RT) enzyme at 3.4 × 10−5 mutations per site per
generation coupled with a rapid generation output rate
of ~1 × 1010 virions per patient per day [1-4], and the
propensity of RT to mediate RNA recombination via* Correspondence: rsun@mednet.ucla.edu
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at ~10 times per replication cycle [5,6]. This genetic
plasticity renders many vaccine candidates effective at
neutralizing only a subspecies of the virus within the pa-
tient, and drives the ongoing challenge of antiretroviral
resistance in HIV-1 therapy. It is therefore of paramount
importance that we gain an understanding of the muta-
tional tolerance of the HIV-1 genome in exquisite detail
to effectively design strategies to prevent, treat, and ul-
timately diminish the damage to human health. Here we
provide a replication capacity (RC) analysis of 57% of the
HIV-1 genome for single point mutations using a high-
throughput genetic approach that combines high-density
mutagenesis with the power of next-generation sequen-
cing (NGS) we term quantitative high resolution genetics
(qHRG). The RC dataset can be further used to assist in
HIV-1 vaccine design, identification of nucleotide-levelntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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drug development - an example of which, using the viral
capsid protein, is given. qHRG can be applied to other
viral pathogens and under any applied selection condi-
tion that may be relevant to viral pathogenesis.
Results
Point mutation library construction
To demonstrate the utility of qHRG on an entire viral
genome we aimed to generate highly dense mutagenic
HIV-1 genomic libraries and monitor the variant fre-
quency change in the population following cell passage.
Each HIV-1 library was generated using the pNL4-3
proviral plasmid as template for PCR with an error-
prone polymerase. Primer pairs corresponding to eight
unique restriction sites that segmented the genome into
seven fragments ranging in size from ~1.3 kb to 2.3 kb
(Figure 1A) were used. Mutant PCR fragments wereFigure 1 HIV-1 mutant library and NGS sample preparation. (A) Genom
approach for NGS sample preparation. Virion cDNA from each mutant viral po
PCR step that uses primers specific to the HIV-1 mutagenized region containi
amino “M” nucleotide positions that identify the specific fragment and popula
molecule concentration is accurately measured, and then decreased for error
PCR using a single primer set containing the remainder of the Illumina adaptsubcloned back into pNL4-3, creating seven distinct
mutant libraries, where one of the seven fragments
contained point mutations, and the remaining six were
genetically wild type (WT). Our fragment based design
of seven distinct libraries was used to maximize se-
quencing of only targeted mutational fragments on the
finite Illumina NGS platform and not waste resources
sequencing WT genomic regions not targeted for error-
prone PCR. Unique molecules obtained after subclon-
ing were maximized to ensure a comprehensive point
mutational analysis in each distinct HIV-1 proviral frag-
ment. We generated an average of five mutations per
genomic kilobase in each library, an amount chosen to
be high enough to detect mutation frequency change
above the de novo rate and limit sequencing demand.
We additionally aimed to achieve significant coverage
at each nucleotide point mutation to minimize the pos-
sible epistatic effects other mutations associated withic region for each HIV-1 mutation library. (B) The two-step PCR amplicon
pulation cell passage is used as template for a HIV-1 specific staggered
ng overhangs with a complex 10 ‘N’ nucleotide tag with two keto “K” or
tion, respectively. PCR products from step one are pooled, the amplicon
correction. The pooled sample is then used as template for a second
er region for NGS.
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calculations. We hypothesized this approach would ‘aver-
age out’ possible epistatic effects between the multiple
mutations inherent in our experimental design (Additional
file 1). To completely eliminate the possibility of any engi-
neered epistatic influence on replication, however, is to
create a library containing only a single mutation per gen-
ome – a rate which becomes more practical to assess
point mutational effects on RC in high throughput with
advances in NGS technology. The libraries obtained were
highly complex, consisting ~ 40,000 to 130,000 unique
viral genomes, with each nucleotide position covered 77
to 204-fold. The total number of distinct mutant HIV-1
genomes is approximately half a million.
Mutant library selection and next-generation sequencing
Each mutant plasmid library was reconstituted into virus,
and passaged in CEM T-lymphocytes in an iterative and
parallel fashion for four rounds. For each passage, super-
natant was collected, titered, and added to ~20 million
cells at a MOI of 0.01 to initiate the next selection round.
Virion RNA was isolated after each passage, reversed tran-
scribed, and quantified using qPCR. Transcript levels for
each input plasmid and all selection rounds were high
enough to maintain the full complexity of each starting li-
brary, and we therefore could accurately quantify relative
frequencies of each variant following each round. Initial
deep sequencing experiments on single amplicon stretches
within the gag, pol, and env genes of the viral genome for
each passage round indicated RC selection was largely
complete by passage round 2 (R2). Furthermore, mutant
complexity is largely retained from DNA plasmid to
reconstituted viral particles during the transfection step,
with a correlation of 85-95% across different libraries. We
therefore focused on the input plasmid libraries and R2
egressed viral libraries for RC analysis across the entire
HIV-1 genome (qPCR transcript levels for each shown in
Additional file 2A). The complete cell culture passage
scheme is provided in Additional file 3. We conceptually
designed a two-step PCR strategy to prepare isolated vir-
ion cDNA that is specific for the NGS Illumina platform
(Figure 1B). Following HIV-1 cDNA generation, the first
PCR step utilizes HIV-1 library specific primers to gen-
erate short (~188 bp) amplicons with each containing a
unique nucleotide sequence tag and constant regions at
each terminus corresponding to the adaptor regions
required for the Illumina sequencing platform. The
generation of each PCR product is confirmed by elec-
trophoresis, and library-specific amplicons are pooled
and subjected to a single sub-saturation PCR affixing
the remaining Illumina adaptor region required for
NGS. The final products were then sequenced on an
Illumina HiSeq2000 machine using paired-end 2 × 100
read parameters. The amplicon-based technique ensuresuniform representation of the entire genome as compared
to traditional shearing methods which often result in
over-representation of DNA fragment ends. The approach
also affords unique nucleotide sequence tags and the
adapter region specific for the Illumina platform in the
primer design, and includes an error-correction step to
clearly distinguish true mutation versus NGS instrument
error from the output sequencing reads. Our strategy
ensures an accurate count for each discrete amplicon
present in the selection pool, which through clustering of
unique sequence tags present on each amplicon, quickly
identifies sequencing errors, a procedure conceptually
similar to a method previously described [7]. However,
our strict limitation on redundancy ensures sequence
space is maximized to achieve error correction without
losing sequencing depth on the finite Illumina platform.
Another key for confident quantification of relative fre-
quencies in this strategy is to have a diverse enough com-
bination of unique sequence tags to cover all individual
WT and mutant species present in the selection pool (see
Methods).Calculation of point mutation replication capacity
The complete RC map of the HIV-1 genome is depicted
in Figure 2. All mutations with a low number of input
sequence counts (<30) were filter removed from analysis.
We obtained RC data at single nucleotide resolution for
57% of the viral genome. Our target sensitivity was to
detect variants as rare as 0.001% of the population, and
achieved this for the majority of amplicons. However,
sensitivity was dependent on amplicon coverage per se-
lection round, and generally varied from 0.0004-0.009%
(Additional file 2B and Additional file 4). Overlapping
amplicon regions where counts and sensitivity were in-
creased is also listed in Additional file 4. The presence
of overlapping amplicon regions, produced from separ-
ate PCR primers, also allowed us to validate the repro-
ducibility of our method and confirm the variability of
PCR efficiencies when using differently tagged primers
was minimal. We analyzed the occurrence frequency
and RC data of each individual mutant present on all
overlapping amplicons. As seen in Additional file 5, the
data shows a high correlation (~90%) for all overlapping
amplicons (arbitrarily termed ‘amplicon 1’ and ‘amplicon
2’ in graphs) for the DNA input library and R2. This
data indicates a very reproducible platform to assess mu-
tational impact. Quantitative comparison of the genetic
compositions of each mutant library pre- (input plasmid)
and post-selection (R2) provides indication of the rela-
tive RC for each individual viral mutation, and is
expressed as a RC index:
RC index = (occurrence frequency in R2)/(occurrence
frequency in plasmid library).
Figure 2 RC map for 57% of nucleotide positions in the pNL4-3 HIV-1 genome. The HIV-1 genome showing the log10 RC index for all 7,314
individual point mutations assessed for RC after library passage in CEM T-lymphocyte cell culture. HIV-1 genomic regions are identified. Color denotes
nucleotide identity of base change: A: blue, C: yellow, G: red, and T: green. An inset high-resolution view of the 3’-LTR region (9442–9446) of
the genome is also highlighted.
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were interrogated by mutations (57% of the genome).
HIV-1 RC was assessed at 3,943 nucleotide positions
for a single alternate base change, 1,459 nucleotide
positions for two alternate base changes, and 151 nu-
cleotide positions for all three possible alternate base
changes, resulting in a total assessment of 7,314 indi-
vidual point mutations. Based on a survey of HIV-1
pNL4-3 mutational phenotypes described in the litera-
ture we determined that the approximate cutoff points
for lethal, attenuated, and tolerated mutational RC
index values are ≤0.1, from 0.1 – 0.2, and ≥0.2, respect-
ively. It should be noted that the numerical scale pre-
sented in our mutational RC dataset should be treated as a
gradient scale as opposed to fixed finite numerical values.
Therefore, caution should be exercised when deducting
definitive phenotypic conclusions for mutational RC indexvalues measured at our approximate cut-off points. In
general, 51% of the point mutations analyzed were le-
thal, 20% were attenuated, and 29% displayed a toler-
ated phenotype. Depicted in Figure 2 is the log10 RC
index for all 7,314 individual HIV-1 point mutations,
with an inset view of the 3’ LTR region of the genome
highlighting the detailed information garnered from the
qHRG platform. A nucleotide stretch from position
9442–9446 is shown in high resolution depicting the
RC impact of mutations by nucleotide identity. The
complete dataset is deposited to the NCBI Sequence
Read Archive (SRA) under accession code BioProject
PRJNA259391. The RC index values for all HIV-1 mis-
sense substitutions and mutations in non-coding re-
gions are provided in Additional file 6. Many silent
mutations in the gag and enzymatic pol region have
lower RC index values than expected. Although this
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possible that our mutation rate (~5 mutations per kb) re-
sulted in an amplified ‘dragging-down’ effect for neutral
mutations especially in enzymatic protein coding regions,
where subsequent deleterious mutations present on the
genome with the mutation of interest created an average
RC value to be lower than expected. We therefore focused
the remainder of our analysis on the missense mutational
dataset. Profile coverage at the amino acid level is shown
by HIV-1 protein in Figure 3 with the number of missense
substitutions (x-axis) for each amino acid position (y-axis)
measured for RC. Our profile predominately achieved 1 to
3 missense substitutions at each interrogated codon with
substitution identities dependent on what can be obtained
by a single base change due to the error-prone mutagenic
PCR strategy used for library construction.
Validation of missense mutation replication capacity
We randomly selected a set of 13 different missense
substitutions that covered a range of RC phenotypesFigure 3 Missense mutational profile coverage at the HIV-1 amino ac
RC at each HIV-1 codon (y-axis) is grouped by HIV-1 protein and provided
of 1–3 missense substitutions at each interrogated codon for all viral protethroughout the HIV-1 genome for validation. We in-
cluded the replicative incompetent protease active site
substitution D25G as a negative control, and compared all
mutant virion RNA levels to WT. Information pertaining
to the HIV-1 genomic region, amino acid substitution,
corresponding DNA mutation, initial DNA coverage, and
a comparison of the RC index and qPCR validation results
for each substitution are shown in Table 1. All mutant vi-
ruses were constructed individually in pNL4-3, sequence
validated, and used to infect CEM T-lymphocyte cells at a
MOI of 0.01 under the same experimental conditions used
for the qHRG profile. Virion RNA was reversed tran-
scribed, and quantified using qPCR. The nanogram RNA
amount for WT and each viral mutant is shown in
Figure 4A. Shown in Figure 4B is the correlation between
the RC index and the qPCR results, the latter expressed as
the fraction [ng mutant RNA]/[ng WT RNA]. The RC
index and qPCR results were very well correlated, with
a Pearson’s correlation of R = 0.97, indicating the results
of the profile largely predict how substitutions willid level. The number of missense substitutions (x-axis) quantified for
as separate histograms. Our profile predominately achieved coverage
ins.
Table 1 qHRG missense mutation experimental validation
HIV-1 genomic region Substitution DNA mutation DNA coveragea RC index qPCR valueb
Capsid A194T G1765A 216 0.189 0.421
Protease D25G A2326G 165 0.068 0.002c
Protease D29G A2338G 178 0.151 0.241
Reverse transcriptase E6K G2565A 353 0.527 0.849
Reverse transcriptase F61S T2731C 150 0.079 0.037
Reverse transcriptase Y501C A4051G 190 0.04 0.037
Integrase N155Y A4692T 90 0.119 0.002c
vif D101N G5341A 223 0.453 0.981
rev E10G A5997G 292 0.698 1.714
gp120 C119G T6575G 123 0.082 0.021
gp120 K205M A6834T 337 0.169 0.123
gp120 D476V A7635T 383 0.024 0.026
gp40 Y136H T8126C 206 0.137 0.012c
3’-LTR N/A C9547T 234 0.18 0.132c
aNumber of mutation initial sequence counts.
bValue obtained from [ng RNA mutant]/[ng RNA WT].
cFor mutants where [ng RNA] < 0.01, ELISA measured [ng p24 mutant]/[ng p24 WT] ratios were averaged into value reported.
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index results to the literature, focusing on substitutions
reported in the integrase region of the genome. We ob-
served an 80% correlation between our profiling dataset
and twenty different integrase viral variants compiled
from eleven separate manuscripts when comparing lethal
versus non-lethal replicative phenotypes (Additional
file 7 – references included).
Application of missense mutation replication capacity
profile
Structural annotation of qHRG RC data can provide
valuable insight to help explain functionalities of viral
proteins for a multitude of aspects relevant to viral repli-
cation and disease progression. Protein RC views in
three-dimensional space allow for the detection of struc-
turally adjacent positions with similar RC costs upon
substitution not readily apparent if focusing on a specific
protein region on the primary sequence. This can aid in
assessing the genetic barriers of resistance in existing
drug binding sites to guide inhibitor optimization, and
can provide for the discovery of altogether novel binding
pockets, where regions of low substitution tolerability
can be used for therapeutic development in combination
with computational techniques.
We focused our HIV-1 missense RC dataset analysis
on the capsid (CA) protein, which is essential for repli-
cation and is originally synthesized as the central com-
ponent of the structural 55 kDa gag polyprotein. CA
mediates immature virion assembly as well as forms a
conical shell comprised of ~1500 molecules as a pre-
dominately hexameric lattice to enclose the viral RNAdiploid genome and associated HIV-1 enzymes upon
gag cleavage and viral maturation [8-11], and lattice
disassembly is an obligatory step early in the replication
cycle [12]. Targeted disruption of the CA conical as-
sembly therefore represents an important unexploited
target for the development of novel HIV/AIDS thera-
peutics [13-15]. Recently, a newly discovered CA inhibitor
(PF-3450074) displaying an antiviral EC50 of 0.57 ±
0.26 μM with a favorable therapeutic index of 121 was re-
ported in the literature [16,17]. The inhibitor binding re-
gion on the hexameric CA assembly (PDB 3H47) [18],
with a labeled inset view of the co-crystal CA-inhibitor
binding orientation (PDB 2XDE) [16], and the chemical
structure of PF-3450074 is shown in Figure 5A. PF-
3450074 specifically binds at the mature CA-CA protein
interface, makes contacts within three binding sub-
pockets (P1-P3), and destabilizes the higher-ordered
capsid cone resulting in potent antiviral activity [16].
HIV-1 viral passage experiments using PF-3450074
chemical analog selection pressure revealed the primary
resistant substitution T107N with secondary substitu-
tions Q67H, K70R, H87P, and L111I after 53 days [16].
Interestingly, mutant virus containing the individual
T107N substitution or all five substitutions were re-
ported to replicate comparably to WT in reporter gene-
based infection assays [16]. However, previous studies
have revealed the importance of these positions for CA
function and/or viral replication [19-22]. Our qHRG
data, strictly measuring RC in cell culture, also reveals
a predominately high RC cost for substitutions arising
in the binding pocket of PF-3450074 and for the resist-
ance positions identified, indicating a very favorable
Figure 4 Validation of the HIV-1 qHRG missense mutational profile. (A) Virion RNA amounts in nanogram for WT and each viral mutant
following CEM T-lymphocyte infection quantified by qPCR. Split histogram shown with average amount of ng RNA from two separate replicates
provided on vertical right axis for lower panel, and vertical left axis for upper panel. HIV-1 mutant identity is given on x-axis. (B) Correlation between
the profile RC index (x-axis) and the qPCR results [ng mutant RNA]/[ng WT RNA] (y-axis) of individual HIV-1 mutants showing a very high Pearson’s
correlation of R = 0.97. Data points are colored according to profile phenotype: tolerated: green, attenuated: blue, and lethal: red.
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rals that may experience prolonged effectiveness upon
clinical use. Shown in Figure 5B is the log10 RC index
for CA substitutions quantified in our profile for each
residue involved in PF-3450074 binding (P1-P3) and
the resistant positions (RP) observed after serial viral
passage under inhibitor pressure. The graphs are color-
coded to represent a tolerant (green), attenuated (blue),
or lethal (red) phenotype depending on the measured
log10 RC index for each CA substitution. For P1, CA
substitutions N53Y, I73M/L, A105P/T/S, T107S, and
Y130F/C all displayed a lethal RC. Two CA substitu-
tions in P1, I73T and A105T, both attenuated with aRC index of 0.12 and 0.14, respectively, were the only
replicatively viable substitutions. At CA P2, L56I/Q,
V59A, M66L/I, L69F/I/S, and I73M/L were all lethal
for replication, with V59G displaying a tolerated pheno-
type (0.48), and I73T attenuated as in P1. At CA P3,
N57Y/I/D, Q63H, M66L/I, Q67L, and K70I/E/R all dis-
played a lethal RC, with Q63K tolerated for RC (0.24),
and Q67H displaying an attenuated phenotype (0.15). At
the CA positions identified as conferring PF-3450074 re-
sistance upon substitution, only the attenuated positions
Q67H, located in P3, and L111P (0.17) were viable for
viral replication. All other CA RP substitutions, Q67L,
K70I/E/R, H87Y/P/Q, and T107S, were lethal for RC. The
Figure 5 Application of the HIV-1 qHRG missense mutational profiling data to aid in CA drug design. (A) Surface representation of CA
hexamer (PDB 3H47), with alternating CA monomers shown in light and dark grey, respectively. The CA binding pocket of PF-3450074 is colored
in cyan. High-resolution inset view also provided highlighting inhibitor binding orientation (PDB 2XDE), with CA protein in light grey, inhibitor
binding residues in cyan, and PF-3450074 in stick representation and colored by element with C in green, O in red, and N in blue. CA positions
are labeled to show drug binding residues (black) and/or resistant positions (white). The small molecule chemical structure of PF-3450074 is
provided with chemical moieties that occupy each CA sub-pocket labeled. (B) The log10 RC index for CA substitutions at positions involved in
PF-3450074 binding (P1-P3) and the resistant positions (RP). The graphs are color-coded to represent a tolerant (green), attenuated (blue), or
lethal (red) phenotype depending on the measured log10 RC index for each CA substitution. WT amino acid identities are horizontally labeled
at the top of each graph, with substitution identities individually labeled for each entry.
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ther aid to maximize the redesign of next-generation
inhibitors binding this CA region while avoiding amino
acid substitution routes with high RC that would likely
lead to the rapid emergence of viral resistance upon in-
hibitor pressure. The use of RC profiling data to inform
rational in silico drug design approaches helps to refine
next-generation antiviral inhibitor design by providing
the substitution routes likely to result in the emergence
of inhibitor resistant viral variants.
Discussion
In this study we used our high-throughput genetic plat-
form to assess the impact of point mutations on viral RCin an X4 laboratory HIV-1 strain in T-lymphocyte cell
culture. The RC of mutations at each nucleotide pos-
ition strictly reflects this experimental condition. Inter-
estingly, mutations that resulted in a RC greater than
the WT pNL4-3 strain (RC index >1) were very rare
and amounted to only 1.9% of the complete dataset
(140 out of 7,314 total mutations) providing indication
that pNL4-3 is already well adapted to cell culture
growth and optimization resulting from substitutions,
at least resulting from one mutational step away from
WT, is not a common occurrence. Our methodology
could be utilized to define nucleotide positions that
confer a RC advantage under other selection conditions
such as HLA escape or drug resistance, or other genetic
Al-Mawsawi et al. Retrovirology  (2014) 11:124 Page 9 of 14backbones such as a M-tropic CCR5 utilizing strain.
Employing qHRG under different HIV-1 relevant selec-
tion conditions with multiple genotypes and compiling
the data will provide a more comprehensive map of the
genetics of HIV-1 pathology. Moreover our RC data
may overlap with sequence conservation information
that is readily available from patient derived HIV-1 se-
quence databases, but conservation of a particular nu-
cleotide position does not strictly equate to a high RC
for that viral position [23,24], but a direct RC advantage
of a select ancestral strain in that particular patient en-
vironment. qHRG provides a complementary, direct,
and functionally-based approach to impartially identify
amino acid residues that are critical for viral replication
in a defined cellular environment. To complement data
collected from naturally occurring variations in clinical
samples, our approach can be applied to study the dy-
namics of viral mutant populations in different growth
conditions with precise control of experimental condi-
tions to directly ascertain the mechanistic interplay be-
tween virus and host.
In the course of applying our genetic profiling approach
on the complete HIV-1 genome, we have identified a
number of improvements that can be incorporated in the
future usage of our methodology. Since multiple muta-
tions were introduced for individual clones in the mutant
libraries in this study, a systematic mutational additive
effect may be present during the quantification of individ-
ual mutation RC. It is possible that our mutation rate
(~5 mutations per kb) resulted in a ‘dragging-down’ ef-
fect for neutral mutations especially in enzymatic protein
coding regions, where subsequent deleterious mutations
present on the genome with the mutation of interest cre-
ated an average RC value to be lower than expected. The
obtainment of larger mutant library pools, which would
afford a higher coverage at each nucleotide position,
would considerably improve the RC data at silent muta-
tional positions exhibiting a neutral phenotype. Longer se-
quencing reads, which are becoming increasingly available
on multiple NGS platforms, would also address epistatic
effects. Additionally, this problem can be resolved by low-
ering the number of mutation rate to 1–2 per clone, which
becomes more feasible and affordable with the increasing
capacity of NGS technology. In addition, the high muta-
tion rate within the HIV-1 replication cycle may increase
the noise of RC profiling and obscure the identification of
a lethal mutation. Mutational assessment could be further
refined by increasing the input occurrence frequency of
individual point mutations by performing random muta-
genesis on a shorter fragment. A more dramatic drop of
occurrence frequency will be detected if a lethal mutation
has a higher occurrence in the input mutant library. In
other words, the calculated RC value will be lower for a le-
thal mutation that has a higher occurrence in the inputmutant library. We anticipate the above technical im-
provements would enrich the quality of the RC profiling
data.
This study represents the first application of our qHRG
method to an entire viral genome – namely HIV-1. How-
ever, our platform will be useful for any virus that can be
genetically manipulated in a laboratory setting. We re-
cently demonstrated the power of our sequencing ap-
proach for viral drug development using the NS5A
protein of hepatitis C (HCV) under the inhibitory pres-
sure of Daclatasvir to help predict clinical outcomes if
development continued to therapeutic use [25]. For in-
fluenza A, we have profiled RC of the hemagglutinin
gene at single-nucleotide resolution [26], profiled for
mutations affecting type 1 interferon sensitivity in the
NS segment [27], and uncovered compensatory muta-
tions to Tamiflu in the neuraminidase gene [28]. As
demonstrated in our HCV study, we show how the
comprehensiveness of qHRG can be increased by apply-
ing saturation mutagenesis for library construction,
which enables the interrogation of every codon for all
possible amino acid substitutions, and removes the ex-
perimental limitation of only examining substitutions
that can be obtained by one mutational step away from
WT. We have also demonstrated the application of our
amplicon-based PCR approach for Illumina NGS to
clinical HIV-1 quasi-species populations in acute infec-
tion [29] and achieved a higher sensitivity in identifying
rare quasi-species variants as compared to published
approaches using other NGS platforms. A number of
groups have also been utilizing high-resolution muta-
tional scanning combined with NGS that targets pro-
teins or protein domains to gain insight into protein
function and evolutionary mutational tolerance [30-35].Conclusions
We have provided a RC map of the HIV-1 genome using
a genetic platform that combines high-density mutagen-
esis with NGS. The utility of such a comprehensive RC
dataset is extensive. Examples include (i) determining re-
gions less tolerable to mutation to aid in vaccine or
therapeutic development, (ii) identification of nucleotide
sequence changes that result in a lethal replication
phenotype, but encode silent substitutions at the amino
acid level – suggesting function at the nucleic acid level,
ie., RNA secondary structure, DNA-protein recognition
signals, or small RNAs, and (iii) structural annotation of
essential amino acids on existing three-dimensional
structures to provide insight into structure-function rela-
tionships. Here, the power of our qHRG platform is the
ability to sensitively quantify the RC of individual viral
variants in a large and diverse population of mutants for
involvement in a replicative pathogenic process within a
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mental platform.
Methods
Viral mutant library preparation
To generate the HIV-1 mutant library we designed a
PCR strategy utilizing the HIV-1 proviral DNA plasmid
pNL4-3 as template and the error-prone polymerase
Mutazyme II (Strategene) to generate the point muta-
tions during PCR amplification. The HIV-1 genome of
the molecular clone pNL4-3 was divided into 7 seg-
ments ranging from ~1.3 to 2.3 Kb. Fragment start and
end sites were selected based on the location of unique
enzyme digest restriction sites within the plasmid. We
further designed primer sets overlapping each distinct
restriction site for error-prone PCR and validated the
primer pairs for efficient PCR amplification. All primers
used in this study are given in Additional file 8. Error-
prone PCR was conducted using the GeneMorph II
Random Mutagenesis Kit (Stratagene) and a starting
target mutagenized fragment region amount of either
0.5 ng (fragment 1, 2, and 6) or 5 ng (fragment 3, 4, 5,
and 7). All error-prone PCR reactions contained an ini-
tial melt step at 95°C for 2 min and a final extension
step at 72°C for 10 min, followed by a final hold at 4°C.
Repetitive error-prone PCR cycle parameters were frag-
ment specific according to optimized primer annealing
temperatures, extension times due to fragment length,
and cycle numbers to obtain a target mutation rate of
as close to ~5 mutations per kilobase as possible. For
each fragment: Frag1: 95°C 30 sec, 63°C 30 sec, 72°C
2 min 15 sec, 40 cycles; Frag2: 95°C 30 sec, 55°C 30 sec,
72°C 1 min 30 sec, 30 cycles; Frag3: 95°C 30 sec, 63°C
30 sec, 72°C 1 min 30 sec, 30 cycles; Frag4: 95°C 30 sec,
63°C 30 sec, 72°C 2 min 15 sec, 40 cycles; Frag5: 95°C
30 sec, 55°C 30 sec, 72°C 1 min 30 sec, 30 cycles; Frag6:
95°C 30 sec, 56°C 30 sec, 72°C 1 min 30 sec, 30 cycles;
Frag7: 95°C 30 sec, 65°C 30 sec, 72°C 1 min 30 sec,
40 cycles. To eliminate WT background contamination
we constructed seven new pNL4-3 vectors, where we
swapped each ~1.3-2.3 kb WT fragment with a small 15
nucleotide fragment that contained the corresponding
restriction sites at either end and a new unique MluI
site within the fragment as a “kill-site” not originally
present in the pNL4-3 vector. The seven vectors were
strictly used to sub-clone each mutant fragment PCR
product back into pNL4-3 resulting in a full length pro-
viral genome, and enabled us to use PCR clean-up col-
umns to remove the 15 base pair insert after vector
digestion resulting in very clean ligations. This cloning
strategy further ensured no WT background species
will contaminate our libraries by (1) using the MluI
kill-site to further remove background, and (2) guaran-
teed that if background was present after ligation theviral genomes would be missing greater than a kilobase
of genome and result in non-viable viral particles.
Mutagenized PCR fragments were ligated into each corre-
sponding digested cloning vector using T4 DNA ligase
(Invitrogen), transformed into chemically competent
DH5α (fragments 2 and 3) or electroporated using a
Gene Pulser II (BioRad) into MegaX DH10B T1R (Invi-
trogen) E.Coli according to manufacturer’s instructions
and plated on four 143 cm2 ampicillin agar plates. For
each fragment, colonies were counted, scraped and
pooled into ~25 mL LB and the plasmid was midi-
prepped (Invitrogen). The mutation rate per fragment
and coverage for each fragment nucleotide position
base change are as follows: Frag1: 4.5 mutations per
711 base pair region; 64,781 colonies obtained resulting
in 134-fold coverage for all mutations at each fragment
position. Frag2: 6 mutations per ~1300 base pair region;
49,968 colonies obtained resulting in 77-fold coverage
for all mutations at each fragment position. Frag3: 10
mutations per ~1500 base pair region; 39,240 colonies ob-
tained resulting in 87-fold coverage for all mutations at
each fragment position. Frag4: 14 mutations per ~2300
base pair region; 54,605 colonies obtained resulting in
110-fold coverage for all mutations at each fragment
position. Frag5: 8.5 mutations per ~1500 base pair re-
gion; 62,598 colonies obtained resulting in 118-fold
coverage for all mutations at each fragment position.
Frag6: 6 mutations per ~1600 base pair region; 79,750
colonies obtained resulting in 99.5-fold coverage for all
mutations at each fragment position. Frag7: 4 muta-
tions per 832 base pair region; 127,406 colonies ob-
tained resulting in 204-fold coverage for all mutations
at each fragment position.
Passage of HIV-1 mutant libraries in CEM T-lymphocyte
cell culture
Each HIV-1 mutant plasmid library was separately trans-
fected in 293T cells for viral propagation. Cell culture
supernatant after transfection and after each CEM T-cell
passage was measured for p24 levels using the CFAR
Virology Core Facility at UCLA, filtered with a 0.22 μM
MCE filter (Fisher Scientific) and subsequently added to
2 × 107 cells (cell number calculated to maintain library
complexities) at a MOI of 0.01 with 2 μg/mL polybrene
to initiate the next selection round. This process was
conducted in an iterative and parallel fashion for four
rounds to select out viral species containing mutations
that deleteriously effect replication capacity. Supernatant
p24 levels were used to estimate MOI. p24 provides a
measurement of viral particle concentration regardless of
potential infectivity, often providing an inflated value for
MOI calculation. We compared the p24 derived MOI cal-
culation with a tissue culture infectious dose (TCID)
limited dilution assay and determined the discrepancy
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(p24 > TCID). For all library selection rounds we main-
tained a low p24 calculated MOI (0.01) to minimize
possible trans-complementation between viral variants
in the same infected cell. Although this MOI can
be considered ≤0.01, further reducing possible trans-
complementation, it was not viewed as an experimental
obstruction as cell numbers for each selection round
were maintained in surplus to assure coverage of the start-
ing library complexities. For each passage, at 24 hours
post infection, cells were centrifuged, PBS washed, and re-
suspended in fresh RPMI media to remove unadsorbed
virus. HIV-1 induced cytopathic effects were visually mon-
itored, and each selection round was typically terminated
~7-10 days post infection. Virion RNA was isolated from
cell culture supernatants using QIAamp Viral RNA kit
(Qiagen) and reverse transcribed to cDNA using Super-
script III Reverse Transcriptase (Invitrogen) using random
hexamers. cDNA was then quantified using sybr green
qPCR with known concentrations of linearized pNL4-3
plasmid as standards and primers specific to the env gp41
region of the viral genome validated for efficiency previ-
ously (m = −3.3, R2 = 0.9985), on a DNA engine Opticon 2
real-time cycler (BioRad), using cycle parameters 95°C
3 min, 95°C 20 sec, 56°C 20 sec, 72°C 45 sec, 40 cycles,
72°C for 10 min, and a final hold at 4°C, and data was fur-
ther used to calculate transcript count.
Next-generation sequencing of virus mutants
We conceptually designed a two-step PCR strategy to
prepare isolated viral RNA (cDNA) after each selection
round that is specific for the NGS Illumina HiSeq 2000
platform. Virion cDNA was used as template to amplify
amplicons that are ~188 nts using HIV-1 specific pri-
mer pairs. The primer space between library fragments
1–7 was constant and therefore not covered in muta-
genic selection: primer space 1–2: nucleotides 705–724,
2–3: nucleotides 1995–2022, 3–4: nucleotides 3477–
3500, 4–5: 5733–5760, 5–6: 7244–7268, and 6–7:
8878–8898. Each primer pair (69 staggered pairs for
genome covered – nucleotides 147–9606, LTR regions
1–146 and 9607–9709 of 5’ and 3’ ends of genome not
sequenced) contains a unique nucleotide tag among
them consisting of 10 random nucleotides to identify
the specific amplicon fragment combined with either
two keto bases “K” (T or G) or two amino bases “M”
(C or A) to identify the DNA input or R2, respectively.
The total number of possible unique nucleotide tag se-
quences is 4,194,304, ensuring that each individual
amplicon in the pool has a unique identifying sequence,
and importantly was diverse enough to cover both WT
and mutant species. The primer pairs also contain part
of the 5’ and 3’ Illumina adapter regions required for
sequencing at their termini. For all HIV-1 specificamplicon PCR reactions of step one we used high-
fidelity KOD DNA polymerase (EMD Millipore) with
the cycle parameters 95°C 2 min, 95°C 20 sec, 56°C
20 sec, 68°C 45 sec, 40 cycles, 68°C for 10 min, and a
final hold at 4°C, with the exception of fragment 1
amplicon 5, and fragment 2 amplicon 1, which utilized
the annealing temperature of 66°C. Once HIV-1 ampli-
con fragments were amplified from each round, an ali-
quot (~5 μL) was electrophoresed on a 3% agarose
gel to confirm PCR product amplification. Aliquots
(~5 μL) of each HIV-1 amplicon product required for
one NGS Illumina HiSeq 2000 sequencing lane were
pooled and spun through a PureLink PCR purification
column (Invitrogen). We have overcome an inherent
NGS error-correction issue by ensuring ten copies of
each amplicon is sequenced in order to distinguish mu-
tation versus sequencing error. Based on manufacture
information at the time we conducted our experiment
the error rate for the HiSeq 2000 NGS platform ranged
from 0.1-1%, whereas the typical output per lane of the
instrument was ≥150 million filtered reads. For all our
calculations, we conservatively estimated the filtered
read output per lane at 120 million reads to ensure we
obtained sufficient coverage per amplicon. In previous
optimization trial experiments using the instrument we
directly observed the error rate as low as 0.1%, a rate
that still poses a significant challenge to accurately call-
ing true mutations versus instrument error in such a
large diverse mutant population. To effectively identify
instrument errors, we precisely quantified the number
of pooled amplicon molecules from PCR step one, and
subsequently decreased the amplicon number to 12
million molecules (typically a dilution of ~12,500X) be-
fore it is used as template for the Illumina specific PCR
in step two ensuring that a median of 10 copies of each
amplicon are present after a sub-saturation (18–20
cycles) PCR.
A cluster containing only three or less reads were fil-
tered removed. In addition, only a mismatch that had an
occurrence of >95% within a cluster was called as a true
mutation. This criteria provided a high statistical confi-
dence with a p-value ≤ 10−9 (binomial exact test) for in-
dividual mutation calling. One potential pitfall was that
it is possible to have two or more WT copies carrying
the same unique nucleotide tag as input for the second
step PCR. This would result in an underestimation of
WT copy number. Nonetheless, the input copy number
for the second PCR was estimated to be ~85,000, which
is 50-fold lower than the unique nucleotide tag com-
plexity. The possibility of having any two different mol-
ecules carrying the exactly same unique nucleotide tag
would be ~0.02% (approximated by Poisson distribu-
tion, λ = 85,000/4,194,304). Therefore, the underestima-
tion of WT copy number is very minimal.
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ants was dependent on amplicon coverage, and there-
fore varied by amplicon and selection round (Additional
file 4). For sensitivity, we typically achieved the ability to
detect mutants as rare as 0.001% in the viral population
after error correction. With the exception of amplicon
F1-A5 (nucleotides 568–704), where coverage was con-
sistently low for both input and R2 (sensitivity range of
0.009-0.01%), and amplicon F1-A4 (nucleotides 417–
567), where coverage was low in R2 (sensitivity of
0.06%), our sensitivity range to detect rare mutations
was 0.0004-0.001% and 0.0008-0.009%, for DNA input
and R2, respectively.
Another important aspect to consider in planning our
high-scale mutation experiment in achieving a sensitivity
after NGS sequencing is to determine true mutation fre-
quency changes above what may be imparted by the
cDNA synthesis error rate at 3.4 × 10−5. We determined
the number of library mutations achieving an input
DNA frequency (mutation coverage/amplicon coverage)
greater than the reported cDNA synthesis error rate. As
can be seen in Additional file 9, frequency of engineered
mutations in our library predominately achieves a log
scale fold-increase above the cDNA synthesis error rate.
The purified PCR step one amplicon pool was mea-
sured via nanodrop, exact DNA molecules calculated,
and diluted appropriately to 12 million molecules per
lane for error-correction (~12,500X). A single sub-
saturation PCR to add on the final regions of the Illu-
mina adapter region was then conducted on the diluted
PCR product using high-fidelity KOD DNA polymerase
(EMD Millipore) with the cycle parameters 95°C 2 min,
95°C 20 sec, 62°C 20 sec, 68°C 45 sec, 20 cycles, 68°C
for 10 min, and a final hold at 4°C. Product from the
second PCR was spun through a PureLink PCR purifi-
cation column (Invitrogen), eluted in dH2O, and a
15 μL aliquot at ~8 ng/μL was provided to the DNA
Microarray Core Facility at UCLA, where the concen-
tration was confirmed by Qubit, the size and quality
confirmed using a Bioanalyzer (Agilent Technologies),
and subsequently sequenced on an Illumina HiSeq2000
machine using paired-end 2 × 100 read parameters.
Raw sequencing data were deposited to the NCBI
Sequence Read Archive (SRA) under accession code
BioProject PRJNA259391.
Recently, similar NGS error-correction approaches of
ensuring redundancy of unique identifying sequences
was independently reported as a means to identify rare
cellular mutations and variants within a single gene fo-
cused pool [7,36]. The study by Jabara et al. used an
8-mer degenerate nucleotide sequence at the cDNA
synthesis step to uniquely identify patient derived HIV-
1 PR variants [36]. Unique sequence tagging at the
cDNA synthesis step would prove highly beneficial ascDNA synthesis errors could also be correctly identi-
fied. However the approach is less amenable to large
scale sequencing projects of high gene diversity and is
more suitable for targeted gene variant pools. Although
these studies share a similar philosophy to overcome
the NGS error-correction issue for the detection of rare
variants, our study includes a further restraint in pre-
cisely limiting the input tagged template copy number
and PCR efficiency during the PCR of step two to ac-
curately control the distribution of cluster count in the
sequencing output to a median cluster size of 10 ampli-
cons. Limiting redundancy input in order to minimize
unnecessary loss of sequencing capacity is also men-
tioned in a recent NGS error-correction study by
Schmitt et al. where the approach was to independently
affix a 12-mer unique sequence tag to both strands of a
sheared size-selected targeted sequence DNA [37].
After NGS sequencing and error correction, the ap-
proximated error frequency was reported at 3.8 × 10−10,
representing a great sensitivity improvement in rare
mutation identification. In this approach the target se-
quence DNA was sheared and size-selected, an ap-
proach more suitable for cellular DNA versus short
viral genome DNA fragments, as we observe DNA
shearing to over-represent DNA termini. As many NGS
error-correction methods are currently being reported
in the literature, the goals of the experiment must be
evaluated and a suitable error-correction approach se-
lected as each has their applications, limitations, and
advantages.
Sequencing data analysis
Sequencing reads were mapped by Burrows-Wheeler
Alignment tool (BWA) [38]. Custom Python scripts were
used to match nucleotide tags, conflate error-corrected
amplicon sequences, and other downstream analyses.
The mutation frequency after selection was determined
by dividing the mutation occurrence by the total popula-
tion count (WT plus variant), whereas the change in fre-
quency was determined by calculating: [R2 frequency/
input frequency] of each mutation.
HIV-1 individual mutant construction
All site directed mutagenesis was conducted with a
two-step PCR approach specific to the HIV-1 genomic
fragment that contained the targeted substitution. Each
substitution and corresponding HIV-1 fragment are as
follows: CA A194T:Frag2, PR D25G:Frag3, PR D29G:
Frag3, RT E6K:Frag3, RT F61S:Frag3, RT Y501C:Frag4, IN
N155Y:Frag4, vif D101N:Frag4, rev E10G:Frag5, gp120
C119G:Frag5, gp120 K205M:Frag5, gp120 D476V:Frag6,
gp41 Y136H:Frag6, and 3’LTR C9547T:Frag7. Using
5 ng of pNL4-3 as template, each forward and reverse
mutagenic primer was combined with the reverse and
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PCR) to generate partial, yet overlapping (at mutagenized
codon) PCR fragments of the full sized fragment using
high-fidelity KOD DNA polymerase (EMD Millipore) with
the cycle parameters 95°C 2 min, 95°C 20 sec, 56°C 20 sec,
68°C 1 min, 30 cycles, 68°C for 10 min, and a final hold at
4°C. Afterwards 5 μL of each purified mutagenic product
was combined in a second PCR using the same conditions
and cycle parameters with only the forward and reverse
fragment primers to generate the full length fragment
containing the mutagenized codon. The products were
digested with restriction enzymes specific to the fragment:
Frag2: BssHII and ApaI, Frag3: ApaI and AgeI, Frag4:
AgeI and EcoRI, Frag5: EcoRI and NheI, Frag6: NheI and
XhoI, and Frag7: XhoI and NcoI (New England BioLabs),
and ligated in correspondingly digested cloning vectors
using T4 DNA ligase (Invitrogen) according to manufac-
turer’s instructions. Mutations were confirmed by sequen-
cing and plasmids were midi-prepped (Invitrogen).
Additional files
Additional file 1: Schematic view of our approach to minimize
epistatic effects other mutations have on our mutation of interest
RC calculation. We achieved a very high sequencing coverage per
mutation of interest (M) which we hypothesized would average out
potential epistatic effects of mutations present on the same mutagenic
Kb fragment. Each line represents the same Kb DNA fragment, with
mutation of interest, M, represented by open circle, mutations associated
with M on each unique DNA molecule are represented by a closed circle.
The average RC value of all unique genomes containing mutation M is
estimated to be main RC of mutation M.
Additional file 2: Profile transcript count and amplicon coverage for
HIV-1 DNA input and R2 mutant libraries. (A) HIV-1 proviral transcript
count per uL for each single nucleotide point library 1–7 (from bottom to
top) for DNA input and R2. Transcript levels for each were high enough to
maintain the full complexity of each starting library, and therefore
guaranteed we could accurately quantify relative frequencies of each
variant. (B) Amplicon coverage of DNA input and R2. Occurrence of
each amplicon listed on vertical y-axis, whereas amplicon identity listed
on x-axis.
Additional file 3: Complete cell culture passage scheme for each
HIV-1 point mutation library for NGS sample preparation. Each HIV-1
mutant plasmid library was first reconstituted into viral libraries via 293T
transfection and subsequently passaged for two iterative rounds in 20
million CEM T-lymphocytes at a MOI of 0.01. Plasmid libraries (input) and
virion cDNA from R2 (output) were used as material for NGS sample
preparation.
Additional file 4: Table of HIV-1 amplicon coverage and mutant
sensitivity.
Additional file 5: Profiling reproducibility analysis of overlapping
amplicons. We observed ~90% correlation for mutations existing on
overlapping amplicon regions for both the input DNA and R2 selection
round. Arbitrarily termed ‘amplicon 1’ and ‘amplicon 2’ in graphs.
Additional file 6: Table of RC index values for all HIV-1 substitutions.
Additional file 7: Table of qHRG profile results in comparison with
HIV-1 integrase viral phenotypes reported in literature.
Additional file 8: Table of oligonucleotides used in this study.
Additional file 9: Frequency of engineered mutations in our
libraries predominately achieves a log scale fold-increase above the
cDNA synthesis error rate. Number of library mutations (y-axis) achievingan input DNA frequency (mutation coverage/amplicon coverage) greater
than the cDNA synthesis error rate (3.4 × 10−5), shown as dashed red line
(set as base line log10 fold change = 0), in log scale fold-increase (x-axis).
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